Free Trial
→ Financial legend: “This is bad, really bad...” (From Weiss Ratings) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
Compare

SMFL vs. EVLO, CMRA, ADTX, EFTR, and STAB

Should you buy Smart for Life stock or one of its competitors? Smart for Life's main competitors and comparable companies include Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aditxt (ADTX), eFFECTOR Therapeutics (EFTR), and Statera Biopharma (STAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Smart for Life compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

0.3% of Evelo Biosciences shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 1.0% of Evelo Biosciences shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Evelo Biosciences has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Smart for Life has a beta of 17.74, meaning that its stock price is 1,674% more volatile than the broader market.

Smart for Life has higher revenue and earnings than Evelo Biosciences. Evelo Biosciences is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Smart for Life N/A N/A N/A

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Smart for Life Neutral

Summary

Smart for Life beats Evelo Biosciences on 6 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Comera Life Sciences?

Smart for Life (NASDAQ:SMFL) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Smart for Life has a beta of 17.74, suggesting that its stock price is 1,674% more volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market.

28.4% of Smart for Life shares are held by institutional investors. 31.7% of Smart for Life shares are held by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Comera Life Sciences has lower revenue, but higher earnings than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Comera Life Sciences N/A N/A N/A

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Comera Life Sciences Neutral

Summary

Smart for Life beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Aditxt?

Smart for Life (NASDAQ:SMFL) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Smart for Life has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Smart for Life's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

In the previous week, Aditxt had 1 more articles in the media than Smart for Life. MarketBeat recorded 1 mentions for Aditxt and 0 mentions for Smart for Life. Smart for Life's average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company Overall Sentiment
Smart for Life Neutral
Aditxt Neutral

Smart for Life has a beta of 17.74, suggesting that its share price is 1,674% more volatile than the broader market. Comparatively, Aditxt has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

28.4% of Smart for Life shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Comparatively, 0.0% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Smart for Life has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
Aditxt$14.34K0.07-$41.71M-$100.79 thousandN/A

Given Smart for Life's higher possible upside, analysts plainly believe Smart for Life is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smart for Life
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Smart for Life beats Aditxt on 10 of the 13 factors compared between the two stocks.

How does Smart for Life compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$8.83N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Smart for Life Neutral

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Smart for Life N/A N/A N/A

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

eFFECTOR Therapeutics has a beta of 2.73, suggesting that its stock price is 173% more volatile than the broader market. Comparatively, Smart for Life has a beta of 17.74, suggesting that its stock price is 1,674% more volatile than the broader market.

Summary

Smart for Life beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Statera Biopharma?

Statera Biopharma (NASDAQ:STAB) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Statera Biopharma has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market. Comparatively, Smart for Life has a beta of 17.74, meaning that its share price is 1,674% more volatile than the broader market.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Smart for Life Neutral

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Smart for Life N/A N/A N/A

28.4% of Smart for Life shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Statera Biopharma has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Statera Biopharma on 5 of the 5 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.78B$7.43B$12.68B
Dividend YieldN/A2.61%2.50%32.08%
P/E Ratio0.00792.52270.9524.83
Price / SalesN/A838.77579.1772.25
Price / CashN/A80.2274.8850.51
Price / BookN/A9.2110.315.85
Net Income-$22.68M$2.85B$3.51B$381.63M

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/AN/AN/AN/A$1K$11.11MN/A110
EVLO
Evelo Biosciences
N/A$0.00
flat		N/AN/A$4KN/AN/A66
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
ADTX
Aditxt
0.0344 of 5 stars		$0.00
-6.3%		N/A-100.0%$2K$14.34KN/A60
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A+0.0%$1KN/AN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 10/18/2026 by MarketBeat.com Staff.
From Our Partners
Elon Musk’s 4th Wealth Window Set to Open by October 30
Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...
Brownstone Research | Sponsoredtc pixel
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...
Weiss Ratings | Sponsoredtc pixel
INSANE DRONE FOOTAGE
New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...
Paradigm Press | Sponsoredtc pixel
The Iran War Isn’t Chaos. It’s Strategy.
Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...
Behind the Markets | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
This high yielding “gold annuity” is starting to move…
Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...
Golden Portfolio | Sponsoredtc pixel
Did you grab your copy yet?
Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...
Profits Run | Sponsoredtc pixel
Trump’s issues shocking Executive Order on U.S. Dollar
Three days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....
Banyan Hill Publishing | Sponsoredtc pixel